These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11462924)

  • 21. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
    Tani S; Murata S; Tamura M; Fukunaga K; Morita M; Hirata Y; Iida H; Kakuno A; Nishigami T; Yamanaka N
    Nihon Shokakibyo Gakkai Zasshi; 2011 Nov; 108(11):1892-901. PubMed ID: 22056711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
    Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
    Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.
    Tse AN; Wu N; Patel D; Haviland D; Kemeny N
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):935-44. PubMed ID: 19221752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study.
    Marumoto M; Yamasaki T; Marumoto Y; Saeki I; Harima Y; Urata Y; Hidaka I; Ishikawa T; Takami T; Segawa M; Yamaguchi Y; Uchida K; Terai S; Sakaida I
    Hepatogastroenterology; 2014; 61(129):162-7. PubMed ID: 24895814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience.
    Trikalinos NA; Zhou A; Doyle MBM; Fowler KJ; Morton A; Vachharajani N; Amin M; Keller JW; Chapman WC; Brunt EM; Tan BR
    J Natl Compr Canc Netw; 2018 Oct; 16(10):1193-1199. PubMed ID: 30323089
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.
    Borbath I; Ceratti A; Verslype C; Demols A; Delaunoit T; Laurent S; Deleporte A; Vergauwe P; Van Maanen A; Sempoux C; Van Cutsem E; Van Laethem JL;
    Ann Oncol; 2013 Nov; 24(11):2824-9. PubMed ID: 23975665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study.
    Nooijen LE; Franken LC; Belkouz A; Oulad Abdennabi I; Besselink MG; Busch OR; Swijnenburg RJ; Klümpen HJ; Erdmann JI
    Am J Clin Oncol; 2021 Oct; 44(10):526-532. PubMed ID: 34469345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
    Butthongkomvong K; Sirachainan E; Jhankumpha S; Kumdang S; Sukhontharot OU
    Asian Pac J Cancer Prev; 2013; 14(6):3565-8. PubMed ID: 23886146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
    Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J
    Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
    Srimuninnimit V; Sriuranpong V; Suwanvecho S
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):255-60. PubMed ID: 24810940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
    Iyer RV; Gibbs J; Kuvshinoff B; Fakih M; Kepner J; Soehnlein N; Lawrence D; Javle MM
    Ann Surg Oncol; 2007 Nov; 14(11):3202-9. PubMed ID: 17705089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial.
    Alberts SR; Reid JM; Morlan BW; Farr GH; Camoriano JK; Johnson DB; Enger JR; Seay TE; Kim GP
    Am J Clin Oncol; 2012 Oct; 35(5):418-23. PubMed ID: 21555932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
    Eng C; Ramanathan RK; Wong MK; Remick SC; Dai L; Wade-Oliver KT; Mani S; Kindler HL
    Am J Clin Oncol; 2004 Dec; 27(6):565-9. PubMed ID: 15577433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.
    Penz M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Lenauer A; Depisch D; Krauss G; Schneeweiss B; Scheithauer W
    Ann Oncol; 2001 Feb; 12(2):183-6. PubMed ID: 11300321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
    Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
    Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
    Patt YZ; Murad W; Fekrazad MH; Baron AD; Bansal P; Boumber Y; Steinberg K; Lee SJ; Bedrick E; Du R; Lee FC
    Cancer Med; 2017 Sep; 6(9):2042-2051. PubMed ID: 28801995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
    Knox JJ; Hedley D; Oza A; Siu LL; Pond GR; Moore MJ
    Ann Oncol; 2004 May; 15(5):770-4. PubMed ID: 15111345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
    Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
    United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.